Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply Dr Stoddard notes that our Viewpoint on the stigma associated with the treatment of opioid use disorder did not discuss naltrexone. In 2010, the US Food and Drug Administration approved the extended-release formulation of naltrexone for relapse prevention of opioid use disorder based on evidence of efficacy against placebo.
The omission in our Viewpoint was intentional. Our goal was to confront the common, inaccurate, and dangerous assertion that long-term therapy with methadone or buprenorphine (both agonist medications) is merely substituting one addiction for another. This misconception inhibits physicians from providing and patients from seeking needed, effective, and compassionate care. As an antagonist medication usually used for less than 6 months, naltrexone does not face the same degree of misunderstanding.
Olsen Y, Sharfstein J. Treatment for Opioid Use Disorder—Reply. JAMA. 2014;312(7):751. doi:10.1001/jama.2014.8432
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: